Italia markets open in 59 minutes

ICAD May 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,04000,0000 (0,00%)
In data: 01:45PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0400
Aperto0,0400
Denaro0,0000
Lettera0,0000
Prezzo d'esercizio2,50
Scadenza2024-05-17
Min-Max giorno0,0400 - 0,0400
Contratto - Min-MaxN/D
Volume10
Open InterestN/D
  • GlobeNewswire

    Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

    NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD's personalized 1-2 year breast cancer risk assessment solution. "We are delighted to receive the device license from Health Canada for the latest version of ProFound Risk, marking a major milestone in our mission

  • GlobeNewswire

    iCAD Reports Financial Results for Second Quarter Ended June 30, 2023

    Company to host conference call and webcast today at 4:30 PM ETNASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023. Highlights: iCAD signs 20-year worldwide development and commercialization agreement with Google Health to integrate Google’s AI technology with its ProFound Detecti

  • GlobeNewswire

    iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader

    Worldwide commercialization agreement offers potential to ease radiologist workload and reduce healthcare disparities for womenNASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it signed an amendment to its development and commercialization agreement with Google Health, which will enable iCAD to integrate Google’s AI technology with its ProFound Breast Health S